Thomas Sciascia - Feb 15, 2024 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Role
Chief Scientific Officer
Signature
/s/ Christopher Galletta, attorney-in-fact
Stock symbol
TRVI
Transactions as of
Feb 15, 2024
Transactions value $
$0
Form type
4
Date filed
2/16/2024, 04:42 PM
Previous filing
Feb 16, 2023
Next filing
May 31, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRVI Stock Option (right to buy) Award $0 +150K $0.00 150K Feb 15, 2024 Common Stock 150K $2.38 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on February 15, 2024. The 150,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 15, 2025 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 15, 2028.